Search
EyePoint Pharmaceuticals Inc
EYPTAdd to Watchlist
13.580USD
+0.430+3.27%
Close 06/18, 16:00（ET）Quotes delayed by 15 min
1.13BMarket Cap
LossP/E TTM
Earnings Forecast
Currency: USD Updated: 2026-06-18The current earnings forecast score of EyePoint Pharmaceuticals Inc is 8.67, ranking 13 out of 157 in the Pharmaceuticals industry. The average price target is 33.00, with a high of 50.00 and a low of 20.00.
Analyst Rating
Based on
12
analysts
Buy
Current Rating
37.000
Target Price
+172.46%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
175
Total
6
Median
8
Average
Company name
Ratings
Analysts
EyePoint Pharmaceuticals Inc
EYPT
12
Amgen Inc
AMGN
38
Biogen Inc
BIIB
38
Eli Lilly and Co
LLY
35
AbbVie Inc
ABBV
34
Vertex Pharmaceuticals Inc
VRTX
34
1
2
3
...
35
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
FAQs
What is EyePoint Pharmaceuticals Inc's expected revenue for the next quarter?
EyePoint Pharmaceuticals Inc's expected revenue is 408.00K.
What is EyePoint Pharmaceuticals Inc's price target?
Analysts forecast that EyePoint Pharmaceuticals Inc's price target is USD 33.00, with the highest forecast at USD 50.00 and the lowest forecast at USD 20.00.
How have EyePoint Pharmaceuticals IncEYPT's recent earnings per share performed?
The market expectation was USD -0.99, while EyePoint Pharmaceuticals IncEYPT's earnings per share (EPS) for the previous quarter was USD -0.81. EPS for the next quarter is expected at USD -0.94.
What is the analyst rating for EyePoint Pharmaceuticals Inc?
Based on the ratings of EyePoint Pharmaceuticals Inc's stock from 12 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.
